drugset / Trial / NCT02030769

Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer

NCT02030769 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Lugol's solution staining was regarded as a gold standard to detect early superficial lesion during esophageal cancer screening using endoscopy. However, the sensitivity and specificity were influenced by mucus and food debris of esophagus. Pronase, a kind of protease, was previously shown to improve the visibility of gastrointestinal tract. It's unknown if the pre-treatment with pronase would also improve the quality of iodine staining in esophagus.A randomized double-blind clinical trial was designed to investigate whether or not pronase might improve detection rate of early esophageal lesion, especially high grade dysplasia and early cancer by improving the esophageal visibility.

Timeline

Start
2014-01
Primary completion
2014-12
Completion
2014-12

Outcome

Met primary endpoint

paper detection rate of ESCC (confirmed by histopathology) was significantly higher in the pronase group than in the control group PMID 36781469 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Promethazine Small molecule 20000 iu Oral

Indications